Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq:
IPHA) (“
Innate” or the “
Company”)
today announced that it will host a virtual investor event on
Wednesday, June 23, 2021, at 2 p.m. CEST / 8 a.m. EDT.
The event will feature presentations and an
interactive Q&A session from the Company's executive leadership
team as well as Martine Bagot, M.D., Ph.D., Professor and Head of
the Dermatology Department at the Saint-Louis Hospital, University
of Paris, France.
Pr. Bagot will present preliminary mycosis
fungoides data from the Company’s Phase 2 TELLOMAK trial evaluating
its lead product, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing
antibody in development for T-cell lymphomas. This preliminary data
will be presented as an oral presentation at the 16th International
Conference on Malignant Lymphoma (16-ICML) on June 22.
Additionally, the Company’s Chief Scientific
Officer, Pr. Eric Vivier, DVM, Ph.D., will present preclinical data
from ANKET™ (Antibody-based
NK cell Engager
Therapeutics), Innate’s proprietary platform for
developing next-generation, multi-functional NK cell engagers.
These new data were presented at the Federation of Clinical
Immunology Societies (FOCIS) Virtual Annual Meeting on June 10.
Details for the Virtual Event |
Date: Wednesday, June 23rd 2021Time: 2-3.30 p.m. CEST/8-9.30 a.m.
EDT |
The live webcast of the event will be available at the following
link:https://edge.media-server.com/mmc/p/drfhb3j8 |
A telephone number will also be made available. Participants may
register in advance of the event at
http://emea.directeventreg.com/registration/7149928. Upon
registration, participants will be provided with dial-in numbers, a
direct event passcode and a unique registrant ID that they may use
10 minutes prior to the event start to access the call. Call
reminders will also be sent to registered participants via e-mail
the day prior to the event.A replay of the webcast will be archived
on Innate’s website for 90 days following the event.This
information can also be found in the Investors section of the
Innate website, www.innate-pharma.com. |
About
ANKET™ANKET™ (Antibody-based
NK cell Engager
Therapeutics) is Innate Pharma's proprietary
platform for developing next-generation, multi-specific NK cell
engagers to treat certain types of cancer. The Company’s latest
innovation, its tetra-specific ANKET molecule, is the first NK cell
engager technology to engage activating receptors (NKp46 and CD16),
a tumor antigen and a cytokine (IL-2v) in a single molecule. This
leverages the advantages of harnessing NK cell effector functions
against cancer cells and also provides proliferation and activation
signals targeted to NK cells.
In preclinical studies, Innate's tri-1 and
tetra-specific technology has demonstrated potent NK cell
activation, cytotoxicity and efficient control of tumor growth in
preclinical models. This versatile fit-for-purpose technology is
creating an entirely new class of molecules to induce synthetic
immunity against cancer.
About Lacutamab:Lacutamab
(IPH4102) is a first-in-class anti-KIR3DL2 humanized
cytotoxicity-inducing antibody, which is currently in clinical
trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan
disease. This group of rare cutaneous lymphomas of T lymphocytes
has a poor prognosis with few efficacious and safe therapeutic
options at advanced stages.
KIR3DL2 is an inhibitory receptor of the KIR
family, expressed by approximately 65% of patients across all CTCL
subtypes and expressed by up 90% of patients with certain
aggressive CTCL subtypes, in particular, Sézary syndrome. It is
expressed by up to 50% of patients with mycosis fungoides and
peripheral t-cell lymphoma (PTCL). It has a restricted expression
on normal tissues.
About TELLOMAK:TELLOMAK is a
global, open-label, multi-cohort Phase 2 clinical trial recruiting
patients with advanced T-cell lymphomas (TCL) in the United States
and Europe. TELLOMAK is expected to recruit up to 150 patients,
with lacutamab evaluated:
- As a single agent in approximately 60
patients with Sézary syndrome who have received at least two prior
systemic therapies, including mogamulizumab.
- As a single agent in approximately 90
patients with mycosis fungoides (MF) who have received at least two
systemic therapies.
In patients with MF, the study is designed to
evaluate the effect of lacutamab according to KIR3DL2 expression.
The study comprises two cohorts in MF, testing lacutamab in KIR3DL2
expressing and non-expressing patients determined at baseline.
These cohorts follow a Simon 2-stage design that will terminate
early if treatment is considered futile. The Sézary syndrome cohort
of the study could enable the registration of lacutamab in this
indication.
The primary endpoint of the trial is objective
response rate. Key secondary endpoints are progression-free
survival, duration of response, quality of life and adverse
events.
About Innate Pharma:Innate
Pharma S.A. is a global, clinical-stage oncology-focused biotech
company dedicated to improving treatment and clinical outcomes for
patients through therapeutic antibodies that harness the immune
system to fight cancer.
Innate Pharma’s broad pipeline of antibodies
includes several potentially first-in-class clinical and
preclinical candidates in cancers with high unmet medical need.
Innate is a pioneer in the understanding of
Natural Killer (NK) cell biology and has expanded its expertise in
the tumor microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Headquartered in Marseille, France, with a US
office in Rockville, MD, Innate Pharma is listed on Euronext Paris
and Nasdaq in the US.
Learn more about Innate Pharma at
www.innate-pharma.com
Information about Innate Pharma
shares:
ISIN codeTicker
codeLEI |
FR0010331421Euronext: IPH Nasdaq: IPHA9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking
information and risk factors:
This press release contains certain
forward-looking statements, including those within the meaning of
the Private Securities Litigation Reform Act of 1995. The use of
certain words, including “believe,” “potential,” “expect” and
“will” and similar expressions, is intended to identify
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. These risks and uncertainties
include, among other things, the uncertainties inherent in research
and development, including related to safety, progression of and
results from its ongoing and planned clinical trials and
preclinical studies, review and approvals by regulatory authorities
of its product candidates, the Company’s commercialization efforts,
the Company’s continued ability to raise capital to fund its
development and the overall impact of the COVID-19 outbreak on the
global healthcare system as well as the Company’s business,
financial condition and results of operations. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2020,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
InvestorsInnate PharmaTel.: +33
(0)4 30 30 30 30investors@innate-pharma.com |
MediaInnate Pharma Tracy Rossin
(Global/US)Tel.: +1 240 801
0076Tracy.Rossin@innate-pharma.comATCG Press Marie
Puvieux (France)Tel.: +33 (0)9 81 87 46
72innate-pharma@atcg-partners.com |
1 Gauthier et al., Cell 2019
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024